
India is grappling with a severe shortage of two cornerstone chemotherapy drugs, cisplatin and carboplatin, as soaring platinum prices, higher import duties, and regulatory delays make production financially unsustainable.
These drugs, critical in treating ovarian, cervical, lung, bladder, head & neck, and testicular cancers, have become increasingly scarce in hospitals across the country, reports The Pharma Letter’s India correspondent.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze